D

    Dianthus Therapeutics Inc. (DNTH)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $105.61
    -0.23 (-0.22%)

    Market Cap: $5.91B

    Last updated: Sep 01, 2026 at 5:00 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    55%(18/33)
    Avg Surprise
    -19.63%
    Streak
    2 Q

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-1.02
    Range$-1.13 - $-0.87
    8 analysts
    EPS Revisions
    2
    0
    7d
    2
    1
    30d
    EPS Estimate Drift
    90d ago$-1.02-0.2%
    60d ago$-1.02-0.2%
    30d ago$-1.02-0.2%
    7d ago$-1.02+0.0%
    Current$-1.02
    Revenue Consensus
    $310500
    Range$0 - $1M
    12 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-0.89
    Range$-1.07 - $-0.67
    8 analysts
    Revenue Consensus
    $895810
    Range$82060 - $2M
    12 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.89---
    Sep 26EST
    		-$-1.02---
    Jun 26
    Reported Aug 4
    		$-0.90$-0.93+3.23%Beat-2.3%
    Mar 26
    Reported May 5
    		$-0.85$-1.10+22.73%Beat-3.7%
    Dec 25
    Reported Mar 9
    		$-1.43$-1.03-38.65%Miss-76.5%
    Sep 25
    Reported Nov 5
    		$-0.97$-0.86-12.79%Miss-31.1%
    Jun 25
    Reported Aug 7
    		$-0.88$-0.86-2.33%Miss-72.5%
    Mar 25
    Reported May 12
    		$-0.82$-0.71-15.49%Miss-51.9%
    Dec 24
    Reported Mar 11
    		$-0.81$-0.76-6.58%Miss-14.1%
    Sep 24
    Reported Nov 7
    		$-0.74$-0.60-23.33%Miss+80.4%
    Jun 24
    Reported Aug 8
    		$-0.51$-0.55+7.27%Beat+41.1%
    Mar 24
    Reported May 9
    		$-0.54$-0.44-22.73%Miss-14.9%
    Dec 23
    Reported Mar 21
    		$-0.71$-1.01+29.70%Beat-136.7%
    Sep 23
    Reported Nov 9
    		$-3.78$-0.56-575.00%Miss-1300.0%
    Jun 23
    Reported Aug 3
    		$-0.87N/A+71.50%Beat-198.7%
    Mar 23
    Reported May 11
    		$-0.47$-0.40-17.50%Miss-20.5%
    Dec 22
    Reported Mar 29
    		$-0.30$-0.28-8.62%Miss+9.1%
    Sep 22
    Reported Nov 3
    		$-0.27$-0.29+6.90%Beat+10.0%
    Jun 22
    Reported Aug 4
    		$-0.29$-0.34+14.71%Beat+9.4%
    Mar 22
    Reported May 16
    		$-0.39$-0.32-22.60%Miss-8.3%
    Dec 21
    Reported Mar 8
    		$-0.33$-0.32-4.13%Miss+13.2%
    Sep 21
    Reported Nov 4
    		$-0.30$-0.33+8.68%Beat+18.9%
    Jun 21
    Reported Aug 5
    		$-0.32$-0.37+14.09%Beat+33.3%
    Mar 21
    Reported May 6
    		$-0.36$-0.39+7.22%Beat+29.4%
    Dec 20
    Reported Mar 3
    		$-0.38$-0.39+2.06%Beat+35.6%
    Sep 20
    Reported Nov 5
    		$-0.37$-0.43+13.95%Beat+31.5%
    Jun 20
    Reported Aug 6
    		$-0.48$-0.54+11.11%Beat+0.0%
    Mar 20
    Reported May 7
    		$-0.51$-0.60+15.00%Beat-15.9%
    Dec 19
    Reported Mar 3
    		$-0.59$-0.58-1.72%Miss-18.0%
    Sep 19
    Reported Nov 13
    		$-0.54$-0.53-1.89%Miss-10.2%
    Jun 19
    Reported Aug 8
    		$-0.48$-0.49+2.04%Beat+84.7%
    Mar 19
    Reported May 9
    		$-0.44$-0.55+20.00%Beat+90.1%
    Dec 18
    Reported Mar 19
    		$-0.50$-0.53+5.66%Beat+51.5%
    Sep 18
    Reported Nov 8
    		$-0.49$-0.67+26.87%Beat-226.7%
    Jun 18
    Reported Aug 9
    		$-3.13$-1.13-176.99%Miss-
    Mar 18
    Reported May 30
    		$-4.45$0.00N/AMiss-
    Dec 17
    Reported Mar 30
    		$-1.03$0.00N/AMiss-
    Mar 17
    Reported Jun 29
    		$-0.15$0.00N/AMiss-

    Key Metrics

    Valuation
    P/E Ratio-25.45EV/EBITDA-7.35x
    Price/FCF-38.00xFCF Yield-2.63%
    Profitability
    Profit Margin0.00%Operating Margin-8079.00%
    ROE-26.10%ROICN/A
    Financial Health
    Debt/EquityN/AInterest CoverageN/A
    Current Ratio26.10xQuick Ratio26.10x
    Trading Statistics
    Beta0.08Avg Volume646.51K
    52-Week High$117.8852-Week Low$23.66

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$110.58
    SMA 20$111.03
    SMA 50$103.81
    SMA 200$74.63
    EMA 10$109.54
    EMA 20$109.31
    EMA 50$103.90
    EMA 200$78.87

    MACD

    Line: 1.28Signal: 2.57Hist: -1.29

    ADX

    ADX: 19.9+DI: 15.9-DI: 24.2

    Aroon & PSAR

    Aroon Up68.0
    Aroon Down4.0
    PSAR$115.17

    Bollinger Bands

    Upper Band$116.59
    Lower Band$105.47
    %B Position1001%(Upper)
    Band Width0.01

    RSI (14-Day)

    Neutral
    46.0

    Momentum Oscillators

    Stoch %K25.9
    Stoch %D36.6
    Williams %R-79.2
    ROC (10d)-8.1%
    Momentum-9.25
    CCI (20d)-220.0
    MFI (14d)59.9

    Volatility Measures

    ATR (14d)$5.06(4.8%)
    StdDev (20d)2.78
    Hist Vol44.2%(High)

    Volume Flow

    VWAP$105.06
    OBV46.4M
    AD Line15.7M
    CMF (20d)0.177

    Volume Metrics

    Avg Vol (20d)636.7K
    Vol Ratio0.7x
    VWMA (20d)$111.33

    Pivot Points

    R3$115.28
    R2$113.29
    R1$109.57
    Pivot Point$107.58
    S1$103.86
    S2$101.87
    S3$98.15

    Advanced Oscillators

    TSI6.90
    Ultimate Osc53.0
    KST75.06

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$761,000$0$873,000$0$0$1.16M$1.33M$2.17M$1.86M$874,000$457,000$924,000
    Cost of Revenue$0$0N/A$0$0$0$78,000$0$0$0$103,000$0
    Gross Profit$761,000$0$873,000$0$0$1.16M$1.33M$2.17M$1.86M$874,000$457,000$924,000
    Operating Expenses$62.24M$47.00M$69.83M$40.68M$35.12M$34.34M$33.24M$32.07M$24.07M$18.72M$13.41M$16.68M
    R&D$48.69M$34.53M$59.90M$32.49M$26.25M$27.00M$26.41M$25.54M$18.07M$13.08M$8.78M$7.96M
    SG&A$13.56M$12.47M$9.93M$8.20M$8.87M$7.34M$6.83M$6.53M$6.00M$5.64M$4.63M$8.72M
    Operating Income$-61,482,000$-46,533,000$-69,541,000$-40,288,000$-34,927,000$-33,177,000$-31,916,000$-29,900,000$-22,204,000$-17,844,000$-12,956,000$-15,759,000
    Interest Income$11.54M$6.26M$5.27M$3.66M$3.40M$3.79M$3.99M$4.45M$4.71M$4.22M$2.44M$1.03M
    Interest Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Income Before Tax$-50,215,000$-40,532,000$-64,713,000$-36,992,000$-31,629,000$-29,511,000$-28,440,000$-25,174,000$-17,607,000$-13,748,000$-10,563,000$-14,763,000
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-50,215,000$-40,834,000$-64,432,000$-36,765,000$-31,629,000$-29,511,000$-28,440,000$-25,174,000$-17,607,000$-13,748,000$-10,563,000$-14,763,000
    EBITDA$-67,304,000$-47,939,000$-70,706,000$-42,862,000$-36,063,000$-35,068,000$-35,237,000$-31,844,000$-22,626,000$-18,381,000$-13,431,000$-16,033,000
    EBIT$-61,757,000$-46,797,000$-69,948,000$-40,650,000$-35,064,000$-33,302,000$-32,578,000$-29,619,000$-22,315,000$-17,970,000$-13,007,000$-15,790,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about DNTH

    News

    DNTH Shares Surge 89% Over the Past Six Months: What's Driving It?

    Dianthus Therapeutics (DNTH) shares have surged 88.9% in the past six months, driven by investor confidence in its lead asset, claseprubart, and a strong financial position. The company is advancing claseprubart for multiple autoimmune diseases, with pivotal phase III trials underway or planned for gMG and CIDP. Additionally, Dianthus's second pipeline candidate, DNTH212, is progressing through phase I studies for several autoimmune disorders, supported by a robust cash reserve of $1.2 billion.

    Eastern Progress•8/22/26•
    Bullish

    Bank of America Corp DE Trims Stake in Dianthus Therapeutics, Inc. $DNTH

    Bank of America Corp DE significantly reduced its stake in Dianthus Therapeutics (NASDAQ:DNTH) by 59.4% in the first quarter, selling over 276,000 shares but still retaining a holding worth approximately $15.8 million. Despite this, institutional investors collectively own 47.53% of the stock, and analysts maintain a "Moderate Buy" rating with an average price target of $124.27. Recent insider selling has also occurred, with over $29 million worth of shares sold in the last three months, even as the company's stock approaches its 52-week high.

    MarketBeat•8/21/26•
    Neutral

    Dianthus Therapeutics director Simon Read sells $326,553 in stock

    Dianthus Therapeutics director Simon Read sold 2,778 shares of company stock for $326,553 on August 19, 2026, after exercising stock options under a Rule 10b5-1 trading plan. The sale occurred near the stock's 52-week high, with the company showing a 401% return over the past year. Despite the insider sale, recent news indicates strong analyst confidence due to positive Q2 earnings, the development of DNTH312, and promising clinical trial data for claseprubart.

    Investing.com•8/20/26•
    Neutral

    Dianthus Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Read Simon

    This document is a statement of changes in beneficial ownership of securities for Director Read Simon of Dianthus Therapeutics, filed as a Form 4. It indicates transactions related to his holdings in the company.

    Moomoo•8/20/26•
    Neutral

    Royal Bank of Canada Has $1.60 Million Stock Holdings in Dianthus Therapeutics, Inc. $DNTH

    Royal Bank of Canada significantly increased its stake in Dianthus Therapeutics, Inc. by 847.5% in the first quarter, now holding 19,064 shares valued at $1.60 million. Despite the company missing EPS estimates, institutional investors collectively own 47.53% of the stock, and Wall Street analysts maintain a "Moderate Buy" rating with an average price target of $124.27. However, recent insider selling, including by the CEO and a director, totals approximately $29.6 million over the past 90 days.

    MarketBeat•8/20/26•
    Neutral

    Frequently Asked Questions About DNTH

    Does DNTH pay dividends?
    Dianthus Therapeutics Inc. (DNTH) does not currently pay a regular dividend.
    What is DNTH's market cap?
    Dianthus Therapeutics Inc. (DNTH) has a market capitalization of $5.91B with a current stock price of $105.61.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In